TVRD earnings
Tvardi Therapeutics Inc. (TVRD) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business UpdateHOUSTON, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi" or the "Company") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today reported its financial and operating results for the third quarter ended September 30, 2026, and provided a business update. Business and Clinical Program Updates: TTI-109 – Ulcerative Colitis (UC) Advancing development plans for TTI-109 in UC. Building on positive Phase 1 healthy volunteer results reported in July and the subsequent selection of UC as its initial target indication, Tvardi is prepa
- Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary FibrosisTvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today provided an update on preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF). The REVERT IPF Phase 2 clinical trial was a randomized, double-blind, placebo-controlled clinical trial of TTI-101 alone or in addition to nintedanib (OFEV®) in patients with IPF. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After reviewing the preliminary safety data and exploratory